Nested case–control study | |
HR (95% CI) | |
logCRP | 1.14 (0.90 to 1.45) |
% of full physical function, per 10 points | 0.88 (0.79 to 0.97) |
No CV disease (Reference) | |
CV disease with therapy | 1.13 (0.65 to 1.98) |
CV disease and no therapy | 2.27 (1.15 to 4.49) |
csDMARD (Reference) | |
TNFi | 0.73 (0.43 to 1.24) |
Other bDMARDs | 0.65 (0.30 to 1.41) |
No of previous bDMARDs | 1.18 (0.86 to 1.62) |
Glucocorticoids, current by 5 mg/day | 0.74 (0.52 to 1.04) |
Non-selective NSAIDs | 1.34 (0.78 to 2.32) |
Cox-2 inhibitors | 1.38 (0.70 to 2.71) |
Patients are censored at the end of the observation (index date) or at the occurrence of other SAEs, whatever comes first.
bDMARD, biological disease-modifying anti-rheumatic drug; COX-2 inhibitors, inhibitors of cyclooxygenase-2.; CRP, C reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; CV, cardiovascular; NSAID, non-steroidal antirheumatic drug; SAE, serious adverse events; TNFi, inhibitors of tumour necrosis factor alpha.